Effects of a 5-lipoxygenase–activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial
H Hakonarson, S Thorvaldsson, A Helgadottir… - Jama, 2005 - jamanetwork.com
ContextMyocardial infarction (MI) is the leading cause of death in the world. Variants in the 5-
lipoxygenase–activating protein (FLAP) gene are associated with risk of MI. ObjectiveTo
determine the effect of an inhibitor of FLAP on levels of biomarkers associated with MI risk.
Design, Setting, and PatientsA randomized, prospective, placebo-controlled, crossover trial
of an inhibitor of FLAP (DG-031) in MI patients who carry at-risk variants in the FLAP gene or
in the leukotriene A4 hydrolase gene. Of 268 patients screened, 191 were carriers of at-risk …
lipoxygenase–activating protein (FLAP) gene are associated with risk of MI. ObjectiveTo
determine the effect of an inhibitor of FLAP on levels of biomarkers associated with MI risk.
Design, Setting, and PatientsA randomized, prospective, placebo-controlled, crossover trial
of an inhibitor of FLAP (DG-031) in MI patients who carry at-risk variants in the FLAP gene or
in the leukotriene A4 hydrolase gene. Of 268 patients screened, 191 were carriers of at-risk …